Search

Vivian K Dullien

from Boulder, CO
Age ~71
Get Report
Also known as:
Vivian Robert Dullien, Vivian F Dullien, Vivian V Dullien, Vivian U Dullien, Vivian K Sullien, Vivian K Dullen
Phone and address:
2212 Stony Hill Rd, Boulder, CO 80305
(303) 499-2224
Related to:
Margaret L Humerick, 78Elise C WilsonJennifer Simerly, 51Ashley Johnson, 41Genna Ward, 39
Connected to:
Caroline E Dullien, 41Shawn P Dulligan, 52Danielle A Dullinger, 48Ronald S Dullinger, 62Kamarr C Dullivan, 46William T Dullivan, 56Cheri G Dullnig, 64Karen A Dullnig, 67Falaq N Dulloo, 64Sharmaine Dulloo, 43

Vivian Dullien Phones & Addresses

  • 2212 Stony Hill Rd, Boulder, CO 80305 (303) 499-2224 (303) 499-6777 (970) 221-9554
  • 2845 Elizabeth St, Fort Collins, CO 80521
  • Pleasanton, CA
  • 2212 Stony Hill Rd, Boulder, CO 80305 (303) 437-6777

Work

Position: Production Occupations

Education

Degree: Associate degree or higher

Resumes

Resumes

Vivian Dullien Photo 1

Owner

View page
Location:
Boulder, CO
Industry:
Biotechnology
Work:
Larta Institute
Principal Advisor
Dullien Associates
Owner
Biex 1991 - 2003
Chief Executive Officer and Founder
Education:
Tufts University School of Medicine 1980
University of New Hampshire
Bachelors, Bachelor of Arts, Zoology
Skills:
Business Strategy
Business Planning
Negotiation
Strategic Planning
Marketing Strategy
Contract Negotiation
Research
Technology Commercialization
Strategy Development
New Business Development
Product Development
Start Ups
Social Media
Change Management
Public Relations
Problem Solving
Fundraising
Entrepreneurship
Competitive Analysis
Intellectual Property
Biotechnology
Entrepreneur
Leadership Development
Venture Capital
Medical Devices
Licensing
Due Diligence
Executive Management
Strategy
Vivian Dullien Photo 2

Principal At Dullien Associates

View page
Location:
Greater Denver Area
Industry:
Biotechnology

Publications

Us Patents

Methods And Formulations For Hydrating Dry Skin, Employing A Low-Energy Beverage

View page
US Patent:
7767239, Aug 3, 2010
Filed:
Nov 21, 2007
Appl. No.:
11/986407
Inventors:
Robert C. Dullien - Boulder CO, US
Vivian Dullien - Boulder CO, US
Assignee:
Dullien Associates, LLC - Boulder CO
International Classification:
A23L 1/30
A61K 8/02
A61K 47/00
US Classification:
426 72, 424401, 424439
Abstract:
There are disclosed beverages for the maintenance of healthy, hydrated skin and the avoidance of dry skin and related problems, for mammals, particularly human beings, comprising whey protein, electrolytes, vitamin C and, optionally, aspartame with a low concentration of sugar, typically 4. 15 g sugar per 237 ml serving, and a ratio of sugar to protein of typically 1. 1:1. Also disclosed are methods for maintaining healthy skin and repairing dry skin by administering these beverages either alone or in conjunction with external topical moisturizers.

Visible Light Modulation Of Mitochondrial Function In Hypoxia And Disease

View page
US Patent:
20100331928, Dec 30, 2010
Filed:
May 12, 2008
Appl. No.:
12/599797
Inventors:
John Dunning - Boulder CO, US
Vivian Dullien - Boulder CO, US
Robert O. Poyton - Lafayette CO, US
Richard Samuel Murdoch - Albuquerque NM, US
Assignee:
Clarimedix - Boulder CO
International Classification:
A61N 5/06
C12N 13/00
C12Q 1/02
A61K 49/00
A61P 43/00
US Classification:
607 88, 4351731, 435 29, 424 91
Abstract:
The present invention provides methods of using electromagnetic radiation in the visible portion of the spectrum to modulate mitochondrial function in the treatment of various conditions, including Alzheimer's disease, other dementias, hypoxia and diabetic peripheral neuropathy, and sensory disorders of the extremities.

Visible Light Modulation Of Mitochondrial Function In Hypoxia And Disease

View page
US Patent:
20130288328, Oct 31, 2013
Filed:
Mar 18, 2013
Appl. No.:
13/846632
Inventors:
Vivian DULLIEN - Boulder CO, US
Robert O. POYTON - Lafayette CO, US
Richard Samuel MURDOCH - Albuquerque NM, US
International Classification:
A61N 5/06
US Classification:
4351731, 607 88
Abstract:
The present invention provides methods of using electromagnetic radiation in the visible portion of the spectrum to modulate mitochondrial function in the treatment of various conditions, including Alzheimer's disease, other dementias, hypoxia and diabetic peripheral neuropathy, and sensory disorders of the extremities.

Hormone Replacement Therapy Monitoring

View page
US Patent:
61746657, Jan 16, 2001
Filed:
Sep 10, 1999
Appl. No.:
9/394579
Inventors:
Vivian Dullien - Boulder CO
Assignee:
Biex, Inc. - Dublin CA
International Classification:
C12Q 100
G01N 3353
US Classification:
435 4
Abstract:
The present invention provides methods for monitoring the effectiveness of hormone replacement therapy in a perimenopausal, early menopausal, or late menopausal woman, comprising testing for hormonal levels in a body fluid of the woman at intervals depending on the stage of menopause, and adjusting levels of replacement hormone administered to the woman based on the test results.

Use Of Estriol Measurement To Monitor Tocolytic Therapy

View page
US Patent:
53701356, Dec 6, 1994
Filed:
Oct 13, 1993
Appl. No.:
8/136219
Inventors:
Vivian K. Dullien - Boulder CO
Assignee:
Biex, Inc. - Boulder CO
International Classification:
A61B 1900
US Classification:
128 898
Abstract:
A method of monitoring tocolytic therapy, which comprises determining a first concentration of estriol in a body fluid of a pregnant patient undergoing or diagnosed as a candidate for undergoing treatment with a tocolytic agent and, based on the value of the first concentration relative to a standard, either initiating, continuing, discontinuing, or modifying the treatment.

Method For Prediction Of Premature Labor

View page
US Patent:
54807760, Jan 2, 1996
Filed:
May 12, 1994
Appl. No.:
8/242034
Inventors:
Vivian K. Dullien - Boulder CO
Assignee:
Biex, Inc. - Boulder CO
International Classification:
G01N 3374
G01N 3353
US Classification:
435 79
Abstract:
A method for detecting the onset of labor in a patient, which comprises analyzing a body fluid of the patient for estriol concentration; correlating the concentration with a standard value; and relating a higher concentration of estriol relative to the standard value as an indication of potential onset of pre-term labor. The standard is usually selected from the group consisting of (1) a predetermined range of estriol concentrations for the body fluid in normal pregnant humans at a preselected time relative to normal, full-term delivery, or (2) a previously measured estriol concentration of the same body fluid of the same pregnant human. Use of this method does not require determination of an estriol/progesterone concentration ratio in the body fluid being test.
Control profile
Vivian K Dullien from Boulder, CO, age ~71 Get Report